AIMS: To evaluate the pharmacokinetics (PK) of five H(1) receptor antagonists in human volunteers after a single oral and intravenous (i.v.) microdose (0.1 mg). METHODS: Five H(1) receptor antagonists, namely NBI-1, NBI-2, NBI-3, NBI-4 and diphenhydramine, were administered to human volunteers as a single 0.1-mg oral and i.v. dose. Blood samples were collected up to 48 h, and the parent compound in the plasma extract was quantified by high-performance liquid chromatography and accelerator mass spectroscopy. RESULTS: The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively. These data were consistent with previously published diphenhydramine data at 500 times the microdose. The rank order of oral bioavailability of the five compounds was as follows: NBI-2 > NBI-1 > NBI-3 > diphenhydramine > NBI-4, whereas the rank order for CL was NBI-4 > diphenhydramine > NBI-1 > NBI-3 > NBI-2. CONCLUSIONS: Human microdosing provided estimates of clinical PK of four structurally related compounds, which were deemed useful for compound selection.
RCT Entities:
AIMS: To evaluate the pharmacokinetics (PK) of five H(1) receptor antagonists in human volunteers after a single oral and intravenous (i.v.) microdose (0.1 mg). METHODS: Five H(1) receptor antagonists, namely NBI-1, NBI-2, NBI-3, NBI-4 and diphenhydramine, were administered to human volunteers as a single 0.1-mg oral and i.v. dose. Blood samples were collected up to 48 h, and the parent compound in the plasma extract was quantified by high-performance liquid chromatography and accelerator mass spectroscopy. RESULTS: The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively. These data were consistent with previously published diphenhydramine data at 500 times the microdose. The rank order of oral bioavailability of the five compounds was as follows: NBI-2 > NBI-1 > NBI-3 > diphenhydramine > NBI-4, whereas the rank order for CL was NBI-4 > diphenhydramine > NBI-1 > NBI-3 > NBI-2. CONCLUSIONS:Human microdosing provided estimates of clinical PK of four structurally related compounds, which were deemed useful for compound selection.
Authors: R C Garner; I Goris; A A E Laenen; E Vanhoutte; W Meuldermans; S Gregory; J V Garner; D Leong; M Whattam; A Calam; C A W Snel Journal: Drug Metab Dispos Date: 2002-07 Impact factor: 3.922
Authors: Graham Lappin; Wilhelm Kuhnz; Roeline Jochemsen; Johannes Kneer; Ajai Chaudhary; Berend Oosterhuis; Willem Jan Drijfhout; Malcolm Rowland; R Colin Garner Journal: Clin Pharmacol Ther Date: 2006-09 Impact factor: 6.875
Authors: James M Armitage; Russell J Erickson; Till Luckenbach; Carla A Ng; Ryan S Prosser; Jon A Arnot; Kristin Schirmer; John W Nichols Journal: Environ Toxicol Chem Date: 2016-12-19 Impact factor: 3.742
Authors: Claudia C Wagner; Marie Simpson; Markus Zeitlinger; Martin Bauer; Rudolf Karch; Aiman Abrahim; Thomas Feurstein; Matthias Schütz; Kurt Kletter; Markus Müller; Graham Lappin; Oliver Langer Journal: Clin Pharmacokinet Date: 2011-02 Impact factor: 6.447
Authors: Colin R Garner; Kevin B Park; Neil S French; Caroline Earnshaw; Alessandro Schipani; Andrew M Selby; Lindsay Byrne; Sarah Siner; Francis P Crawley; Wouter H J Vaes; Esther van Duijn; Rianne deLigt; Heili Varendi; Jane Lass; Grzegorz Grynkiewicz; Wioletta Maruszak; Mark A Turner Journal: Br J Clin Pharmacol Date: 2015-06-01 Impact factor: 4.335